Phase 2/3 study on refractory or relapsed T cell lymphoma2019-04-08T11:40:39+00:00

Project Description

Phase 2/3 study on refractory or relapsed T cell lymphoma

Brief

T cell lymphoma is an hematologic cancer in which T cells are becoming malignant. This is a non-hodgkin lymphoma. This disease involves the bone marrow and can occur in both adult and children. This is one of the most frequent blood disease. Relapse are occurring often, with a lot of resistance to therapies.

Goals

  • To find 3 medical centers with a high rate of patients recruitment, 
  • To sign with all 3 centers a Clinical Trial Agreement and negotiate a budget per patient according to Sponsor’s guidelines and recommendations, 
  • To obtain Local Ethical Committee approvals in the conduct of the Trial, 
  • To obtain Ministry of Health’s approval in the conduct of the Trial for Israel, 
  • To recruit 100% of the recruitment patient potential (15 patients) on 12 months, 

Want To Work With Us?

WE WILL BE HAPPY TO WORK WITH YOU.

Contact Us